Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN APOKYN — Total revenues

Other product segments

Qelbree
$77.84M+20.2%
GOCOVRI
$35.24M+14.8%
Royalty, licensing, and other revenues
$29.31M+274%
Collaboration revenue (ZURZUVAE)
$27.64M—
Trokendi XR
$9.48M-26.0%
ONAPGO
$8.38M—
Oxtellar XR
$7.42M-27.2%
Other
$4.67M-45.6%

Similar metrics at other companies

AbbVie logo
ABBVEpkinly — Net revenues
$83M+62.7%
Tarsus Pharmaceuticals, Inc. logo
TARSProduct sales, net — Total revenues
$145.39M+85.6%
Gilead Sciences logo
GILDProduct sales — Total revenues
$6.95B+5.0%
Amgen logo
AMGNKRYSTEXXA — Total revenues
$255M+8.1%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%
Exelixis logo
EXELNet product revenues — Total revenues
$554.98M+8.1%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's apokyn — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's APOKYN — total revenues?
Supernus Pharmaceuticals (SUPN) reported APOKYN — total revenues of $7.73M in Q1 2026.
How has Supernus Pharmaceuticals's APOKYN — total revenues changed year-over-year?
Supernus Pharmaceuticals's APOKYN — total revenues decreased by 48.4% year-over-year, from $14.98M to $7.73M.
What is the long-term trend for Supernus Pharmaceuticals's APOKYN — total revenues?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's APOKYN — total revenues has grown at a -16.7% compound annual growth rate (CAGR), from $99.23M to $47.77M.
What does APOKYN — total revenues mean?
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic line within the company's neuroscience portfolio. It serves as a key indicator of the product's market adoption, commercial performance, and contribution to the overall top-line growth of the organization. Tracking this revenue stream helps investors evaluate the lifecycle stage and competitive positioning of the specific treatment.